Skip to main navigation Skip to search Skip to main content

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

  • Steven P Treon
  • , Kirsten Meid
  • , Joshua Gustine
  • , Christopher J Patterson
  • , Jeffrey V. Matous
  • , Irene M. Ghobrial
  • , Jorge J Castillo
  • Harvard University
  • Colorado Blood Cancer Institute, Denver, CO

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume126
Issue number23
DOIs
StatePublished - Dec 3 2015
Externally publishedYes

Disciplines

  • Medicine and Health Sciences
  • Gastroenterology
  • Surgery
  • Internal Medicine

Cite this